Literature DB >> 15349910

Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation.

Montserrat Garcia-Retortillo1, Xavier Forns, Josep M Llovet, Miquel Navasa, Anna Feliu, Anna Massaguer, Miquel Bruguera, Josep Fuster, Juan Carlos Garcia-Valdecasas, Antoni Rimola.   

Abstract

Preliminary reports suggested that hepatitis C virus (HCV) infection has a more aggressive course following living donor liver transplantation (LDLT) compared to cadaveric liver transplantation (CLT). The aim of this prospective study was to establish if HCV disease recurrence differs between LDLT and CLT. A cohort of 116 consecutive HCV-infected patients undergoing 117 LTs in a single center from March 2000 to August 2003 were followed-up, including systematic liver biopsies. Severe recurrence (SR) was defined as biopsy-proven cirrhosis and/or the occurrence of clinical decompensation. After a median follow-up of 22 months (2.6-44 months), 26 (22%) patients developed SR (decompensation in 12), involving 17 (18%) of 95 patients undergoing CLT and 9 (41%) of 22 undergoing LDLT. The 2-year probability of presenting SR was significantly higher in LDLT compared to CLT (45% vs. 22%, P = .019). By univariate analysis LDLT (P = .019) and an ALT higher than 80 IU/L 3 months after LT (P = .022) were predictors of SR. In 93 patients from whom a liver biopsy was available 3 months after LT, a lobular necroinflammatory score >1 (P < .01), LDLT (P < .01), and biliary complications (P = .046) were associated with SR. However, the only variables independently associated with SR were LDLT (odds ratio [OR], = 2.8; 95% CI,1.19-6.6; P = .024) and a lobular necroinflammatory score > 1 (OR, 3.1; 95% CI, 1.2-8; P = .013). In conclusion, HCV recurrence is more severe in LDLT compared to CLT. Although our results were based on a single-center experience, they should be considered in the decision-making process of transplant programs, since severe HCV recurrence may ultimately compromise graft and patient survival. Copyright 2004 American Association for the Study of Liver Diseases

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15349910     DOI: 10.1002/hep.20357

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  26 in total

Review 1.  Living donor liver transplantation to patients with hepatitis C virus cirrhosis.

Authors:  Yasuhiko Sugawara; Masatoshi Makuuchi
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

2.  A high MELD score, combined with the presence of hepatitis C, is associated with a poor prognosis in living donor liver transplantation.

Authors:  Toru Ikegami; Ken Shirabe; Shohei Yoshiya; Tomoharu Yoshizumi; Yo-Ichi Yamashita; Norifumi Harimoto; Takeo Toshima; Hideaki Uchiyama; Yuji Soejima; Yoshihiko Maehara
Journal:  Surg Today       Date:  2013-02-23       Impact factor: 2.549

Review 3.  Living donor liver transplantation for hepatitis C.

Authors:  Yasutsugu Takada; Shinji Uemoto
Journal:  Surg Today       Date:  2012-10-06       Impact factor: 2.549

4.  Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation.

Authors:  Norah A Terrault; Mitchell L Shiffman; Anna S F Lok; Sammy Saab; Lan Tong; Robert S Brown; Gregory T Everson; K Rajender Reddy; Jeffrey H Fair; Laura M Kulik; Timothy L Pruett; Leonard B Seeff
Journal:  Liver Transpl       Date:  2007-01       Impact factor: 5.799

5.  Recent advances in liver transplantation for the practicing gastroenterologist.

Authors:  Ranjan Mascarenhas; Ahmet Gurakar
Journal:  Gastroenterol Hepatol (N Y)       Date:  2009-06

6.  Addition of adult-to-adult living donation to liver transplant programs improves survival but at an increased cost.

Authors:  Patrick G Northup; Michael M Abecassis; Michael J Englesbe; Jean C Emond; Vanessa D Lee; George J Stukenborg; Lan Tong; Carl L Berg
Journal:  Liver Transpl       Date:  2009-02       Impact factor: 5.799

7.  Antiviral treatment for hepatitis C virus infection after liver transplantation.

Authors:  Yasuhiko Sugawara; Sumihito Tamura; Norihiro Kokudo
Journal:  Hepat Res Treat       Date:  2010-11-01

8.  Strategies to reduce hepatitis C virus recurrence after liver transplantation.

Authors:  Ruben Ciria; María Pleguezuelo; Shirin Elizabeth Khorsandi; Diego Davila; Abid Suddle; Hector Vilca-Melendez; Sebastian Rufian; Manuel de la Mata; Javier Briceño; Pedro López Cillero; Nigel Heaton
Journal:  World J Hepatol       Date:  2013-05-27

9.  Prevention of hepatitis C recurrence after liver transplantation: An update.

Authors:  Marco Carbone; Ilaria Lenci; Leonardo Baiocchi
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-08-06

Review 10.  Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem.

Authors:  Alberto Grassi; Giorgio Ballardini
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.